<DOC>
	<DOCNO>NCT01888445</DOCNO>
	<brief_summary>This study evaluate safety efficacy intermittent oral dose ASP1517 dialysis chronic kidney disease patient anemia .</brief_summary>
	<brief_title>A Study Investigate Effect ASP1517 After Intermittent Oral Dosing Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin Reference Drug</brief_title>
	<detailed_description>To evaluate safety dose-response ASP1517 hemoglobin ( Hb ) correction ASP1517 apply intermittently dialysis chronic kidney disease patient anemia . To evaluate treatment effect Hb maintenance ASP1517 administer intermittently dialysis chronic kidney disease patient anemia .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Patients diagnose endstage kidney disease ( ESKD ) receive stable chronic maintenance dialysis 3 time per week ≥ 12 week Patients receive ESA least 8 week dose ESA within dose range ESA label Hb value screen test ≥10.0 g/dL Receiving hemodialysis via arteriovenous fistula ( AVF ) arteriovenous graft ( AVG ) via permanent catheter Most recent two Hb value dialysis washout period must &lt; 9.5 g/dL one two Hb value must test first visit week Proliferative retinopathy , agerelated macular degeneration , retinal vein occlusion and/or macular edema consider require treatment Immunological disease severe inflammation assess Investigator ; even inflammation remission , subject exclude ( e.g . lupus erythematosus , rheumatoid arthritis , Sjogren 's syndrome , celiac disease , etc ) Having history gastric/intestinal resection consider influential absorption drug gastrointestinal tract active gastroparesis Uncontrollable hypertension ( SBP ≥160 mmHg DBP ≥110 mmHg , dialysis , screen test ) Congestive heart failure ( NYHA classification III high ) Having history hospitalization stroke , myocardial infarction lung infarction within 24 week 1st registration Positive following : human immunodeficiency virus ( HIV ) ; hepatitis B surface antigen ( HBsAg ) ; antihepatitis C virus antibody ( antiHCV Ab ) Anemia anemia due low/absent renal production EPO ( e.g. , iron deficiency anemia , hemolytic anemia , pancytopenia , etc ) Pure red cell aplasia Using anabolic androgenic steroid , testosterone enanthate mepitiostan within 6 week 1st registration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Renal anemia</keyword>
	<keyword>Chronic Renal Failure</keyword>
	<keyword>ASP1517</keyword>
</DOC>